Presentation2_Mimicking acute airway tissue damage using femtosecond laser nanosurgery in airway organoids.zip by Lara Gentemann (3955640)

“…In combination with a precise damage induction via femtosecond laser-based nanosurgery, this model might allow for the examination of intra- and intercellular dynamics in the course of repair processes with a high spatio-temporal resolution, which can hardly be reached using in vivo approaches. …”

Video1_Mimicking acute airway tissue damage using femtosecond laser nanosurgery in airway organoids.AVI by Lara Gentemann (3955640)

“…In combination with a precise damage induction via femtosecond laser-based nanosurgery, this model might allow for the examination of intra- and intercellular dynamics in the course of repair processes with a high spatio-temporal resolution, which can hardly be reached using in vivo approaches. …”

ClOO• determination using TMB (a, b) and DPPH (c,d) method. by Hiroyuki Kawata (4002656)

Ln(Mean number of agents—2.2) versus AIB, black points with standard deviation are data and red is a linear fit. by G. Jordan Maclay (11714526)

Table_2_Elevated triglyceride-glucose index associated with increased risk of diabetes in non-obese young adults: a longitudinal retrospective cohort study from multiple Asian coun... by Jian Han (211805)

“…A non-linear relationship was observed with an inflection point at 7.3. …”

Table_3_Elevated triglyceride-glucose index associated with increased risk of diabetes in non-obese young adults: a longitudinal retrospective cohort study from multiple Asian coun... by Jian Han (211805)

“…A non-linear relationship was observed with an inflection point at 7.3. …”

Table_1_Elevated triglyceride-glucose index associated with increased risk of diabetes in non-obese young adults: a longitudinal retrospective cohort study from multiple Asian coun... by Jian Han (211805)

“…A non-linear relationship was observed with an inflection point at 7.3. …”

Table_4_Elevated triglyceride-glucose index associated with increased risk of diabetes in non-obese young adults: a longitudinal retrospective cohort study from multiple Asian coun... by Jian Han (211805)

“…A non-linear relationship was observed with an inflection point at 7.3. …”

Effects of bortezomib/venetoclax on the growth suppression of sLCL 381 xenografts in SCID mice. by Kam Pui Tam (19746865)

Lentivirus shRNA knockdown experiment and MTT analysis showing the effect of bortezomib/venetoclax on the cell viability of sLCL 381 and 421 panels. by Kam Pui Tam (19746865)

Raw data of the charts in Fig 5. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Antibodies used in western blot analysis. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 3. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 1. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 6. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 2. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Synergy scores computed by SynergyFinder. by Kam Pui Tam (19746865)

Viability of additional sLCLs upon treatment of bortezomib and venetoclax. by Kam Pui Tam (19746865)

sLCL 381 and 421 panels were observed by fluorescence microscopy (10X). by Kam Pui Tam (19746865)

Synergistic apoptosis, DNA damage response and inhibition of NF-κB induced by bortezomib/venetoclax was related to the expression of BHRF-1, LMP-1, EBNA-3C and botezomib-induced No... by Kam Pui Tam (19746865)